Design Therapeutics, Inc.
DSGN
$14.83
$0.443.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 4.13% | -6.49% | 10.43% | 22.84% | 49.66% |
| Gross Profit | -4.13% | 6.49% | -10.43% | -22.84% | -49.66% |
| SG&A Expenses | -0.72% | 5.67% | 4.56% | 8.05% | 28.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.82% | -3.49% | 8.84% | 18.87% | 43.38% |
| Operating Income | -2.82% | 3.49% | -8.84% | -18.87% | -43.38% |
| Income Before Tax | -5.67% | 0.45% | -17.19% | -30.36% | -61.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.67% | 0.45% | -17.19% | -30.36% | -61.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.67% | 0.45% | -17.19% | -30.36% | -61.82% |
| EBIT | -2.82% | 3.49% | -8.84% | -18.87% | -43.38% |
| EBITDA | -2.84% | 3.50% | -8.87% | -19.03% | -43.82% |
| EPS Basic | 3.87% | 8.01% | -13.12% | -29.57% | -60.96% |
| Normalized Basic EPS | 3.91% | 8.05% | -13.09% | -29.60% | -61.01% |
| EPS Diluted | 3.87% | 8.01% | -13.12% | -29.57% | -60.96% |
| Normalized Diluted EPS | 3.91% | 8.05% | -13.09% | -29.60% | -61.01% |
| Average Basic Shares Outstanding | 9.93% | 8.24% | 3.62% | 0.58% | 0.54% |
| Average Diluted Shares Outstanding | 9.93% | 8.24% | 3.62% | 0.58% | 0.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |